Kane Biotech Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| KNBIF | IOT.V | SBTX.L | NIKI | CLGN | ET80.F | |
|---|---|---|---|---|---|---|
| Market cap | 4.61M | 3.54M | 12.05M | 5.27M | 12.18M | 5.30M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | — | 24.6 | — | -10.8 | — |
| Price/book | -6.3 | 1.4 | 1.5 | 0.1 | 2.1 | 0.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +3.21% | −70.83% | −70.00% | −87.43% | −80.60% | −16.51% |
| Today | 0.00% | −7.14% | −11.43% | −3.98% | +2.92% | +0.95% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All KNBIF news ›Kane Biotech Signs Canadian Distribution Deal With Stevens For Revyve Wound-Care Products
Kane Biotech (KNE.V) said Tuesday it signed a non-exclusive distribution agreement with The Stevens Company for its Health Canada-licensed Revyve wound-care products across Canada. Effective October 1, 2026, the agreement authorizes…
More from 1 other outlet
Kane Biotech Announces $250,000 Insider Loan
The Loan does not bear interest and is repayable on demand. No bonus was paid or is payable by the Company in connection with the Loan. The Company intends to use the proceeds for general working capital and corporate purposes and intends…
Kane Biotech Signs Distribution Agreement with The Stevens Company
Expands Kane Biotech’s commercial footprint and access to the revyve® product line across Canada Under the agreement, Stevens will be authorized to purchase and resell revyve Antimicrobial Wound Gel in 1 oz and 3 oz formats and revyve…
Kane Engages Independent Trading Group as Market Maker
ITG will trade common shares of Kane Biotech on the TSXV and other trading venues in accordance with applicable TSXV policies and other applicable laws, with the objective of maintaining a reasonable market and improving the liquidity of…
Kane Biotech Announces Second Quarter 2026 Financial Results
WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results. Cash at June 30, 2026 was $854,729. Kane Biotech's…
Kane Biotech to Host Commercial Update Webcast on September 16
The details of the Webcast are as follows: Investors, shareholders and other stakeholders are encouraged to register in advance to participate in the live webcast and Q&A session. A replay of the webcast will be made available at…
Kane Biotech Announces Engagement of DNA Advisors
WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive…
Kane Biotech Announces Grant of Stock Options
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 29, 2026 (GLOBE NEWSWIRE) -- Kane ... Kane Biotech Announces Grant of Stock Options Not for distribution to U.S. news wire…
Kane Biotech to Present Clinical Data and Showcase revyve® Product Line at SAWC Fall 2026
WINNIPEG, Manitoba, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a biotechnology company commercializing and developing technologies and products that address microbial…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com8
- stocktitan.net3
- globenewswire.com2
- digitaljournal.com1
- kdhnews.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 20 articles, not a forecast.